{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:21:32Z","timestamp":1781900492958,"version":"3.54.5"},"reference-count":20,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":2845,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To evaluate the efficacy and long-term safety of linagliptin added to basal insulins in type 2 diabetes inadequately controlled on basal insulin with or without oral agents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>A total of 1,261 patients (HbA1c \u22657.0% [53 mmol\/mol] to \u226410.0% [86 mmol\/mol]) on basal insulin alone or combined with metformin and\/or pioglitazone were randomized (1:1) to double-blind treatment with linagliptin 5 mg once daily or placebo for \u226552 weeks. The basal insulin dose was kept unchanged for 24 weeks but could thereafter be titrated according to fasting plasma glucose levels at the investigators\u2019 discretion. The primary end point was the mean change in HbA1c from baseline to week 24. The safety analysis incorporated data up to a maximum of 110 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>At week 24, HbA1c changed from a baseline of 8.3% (67 mmol\/mol) by \u22120.6% (\u22126.6 mmol\/mol) and by 0.1% (1.1 mmol\/mol) with linagliptin and placebo, respectively (treatment difference \u22120.65% [95% CI \u22120.74 to \u22120.55] [\u22127.1 mmol\/mol]; P &amp;lt; 0.0001). Despite the option to uptitrate basal insulin, it was adjusted only slightly upward (week 52, linagliptin 2.6 IU\/day, placebo 4.2 IU\/day; P &amp;lt; 0.003), resulting in no further HbA1c improvements. Frequencies of hypoglycemia (week 24, linagliptin 22.0%, placebo 23.2%; treatment end, linagliptin 31.4%, placebo 32.9%) and adverse events (linagliptin 78.4%, placebo 81.4%) were similar between groups. Mean body weight remained unchanged (week 52, linagliptin \u22120.30 kg, placebo \u22120.04 kg).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Linagliptin added to basal insulin therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia or body weight.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc12-2718","type":"journal-article","created":{"date-parts":[[2013,9,24]],"date-time":"2013-09-24T05:24:42Z","timestamp":1380000282000},"page":"3875-3881","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":114,"title":["Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes"],"prefix":"10.2337","volume":"36","author":[{"given":"Hannele","family":"Yki-J\u00e4rvinen","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Helsinki, Helsinki and Minerva Foundation Institute for Medical Research, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Dur\u00e1n-Garcia","sequence":"additional","affiliation":[{"name":"Valme Hospital Medical School, University of Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Pinnetti","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipta","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Thiemann","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Patel","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Ltd., Bracknell, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Juergen","family":"Woerle","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2013,11,13]]},"reference":[{"key":"2022031222193383100_B1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/diacare.29.03.06.dc05-0695","article-title":"Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients","volume":"29","author":"Rosenstock","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031222193383100_B2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","article-title":"A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"29","author":"Hermansen","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031222193383100_B3","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031222193383100_B4","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc06-1357","article-title":"Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups","volume":"30","author":"Yki-J\u00e4rvinen","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031222193383100_B5","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"2022031222193383100_B6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1463-1326.2011.01458.x","article-title":"Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin","volume":"13","author":"Graefe-Mody","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031222193383100_B7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.2012.04173.x","article-title":"Pharmacokinetics of linagliptin in subjects with hepatic impairment","volume":"74","author":"Graefe-Mody","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2022031222193383100_B8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","article-title":"Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes","volume":"12","author":"Vilsb\u00f8ll","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"2022031222193383100_B9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1185\/03007995.2012.665046","article-title":"Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin","volume":"28","author":"Barnett","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2022031222193383100_B10","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1463-1326.2009.01124.x","article-title":"Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia","volume":"11","author":"Rosenstock","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2022031222193383100_B11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-2008-1058090","article-title":"Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus","volume":"40","author":"Fonseca","year":"2008","journal-title":"Horm Metab Res"},{"key":"2022031222193383100_B12","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00125-007-0633-0","article-title":"Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes","volume":"50","author":"Fonseca","year":"2007","journal-title":"Diabetologia"},{"key":"2022031222193383100_B13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/dom.12020","article-title":"Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus","volume":"15","author":"Kothny","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031222193383100_B14","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031222193383100_B16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2337\/dc07-1572","article-title":"Is glycemic control improving in U.S. adults?","volume":"31","author":"Hoerger","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031222193383100_B17","first-page":"435","article-title":"Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control","volume":"12","author":"Willey","year":"2006","journal-title":"Am J Manag Care"},{"key":"2022031222193383100_B18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3810\/pgm.2012.01.2525","article-title":"Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs","volume":"124","author":"Bron","year":"2012","journal-title":"Postgrad Med"},{"key":"2022031222193383100_B19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1345\/aph.1Q352","article-title":"Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database","volume":"46","author":"Simeone","year":"2012","journal-title":"Ann Pharmacother"},{"key":"2022031222193383100_B20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/dmd.109.031476","article-title":"The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans","volume":"38","author":"Blech","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"2022031222193383100_B21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2337\/dc12-0706","article-title":"Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study","volume":"36","author":"McGill","year":"2013","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/12\/3875\/615545\/3875.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/12\/3875\/615545\/3875.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:34:13Z","timestamp":1647131653000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/12\/3875\/33176\/Effects-of-Adding-Linagliptin-to-Basal-Insulin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,13]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,11,13]]},"published-print":{"date-parts":[[2013,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc12-2718","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,13]]}}}